138 related articles for article (PubMed ID: 9825814)
1. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test.
Schrama YC; Hené RJ; de Jonge N; Joles JA; Van Rijn HJ; Bär DR; Ververs TF; Van Tol A; Koomans HA
Transplantation; 1998 Nov; 66(9):1175-81. PubMed ID: 9825814
[TBL] [Abstract][Full Text] [Related]
2. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
Goldberg RB; Roth D
Am J Cardiol; 1995 Jul; 76(2):107A-109A. PubMed ID: 7604782
[TBL] [Abstract][Full Text] [Related]
3. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
Li PK; Mak TW; Chan TH; Wang A; Lam CW; Lai KN
Transplantation; 1995 Oct; 60(7):652-6. PubMed ID: 7570971
[TBL] [Abstract][Full Text] [Related]
4. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
5. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients.
Martínez-Castelao A; Grinyó JM; Fiol C; Castiñeiras MJ; Hurtado I; Gil-Vernet S; Serón D; Porta I; Miñarro A; Villarroya A; Alsina J
Kidney Int Suppl; 1999 Jul; 71():S231-4. PubMed ID: 10412785
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine.
Goldberg R; Roth D
Transplantation; 1996 Dec; 62(11):1559-64. PubMed ID: 8970607
[TBL] [Abstract][Full Text] [Related]
10. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
Smit JW; Jansen GH; de Bruin TW; Erkelens DW
Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787
[TBL] [Abstract][Full Text] [Related]
11. Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience.
Jardine A; Holdaas H
J Clin Pharm Ther; 1999 Dec; 24(6):397-408. PubMed ID: 10651972
[TBL] [Abstract][Full Text] [Related]
12. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
13. The interaction of fluvastatin and cyclosporin A in renal transplant patients.
Li PK; Mak TW; Wang AY; Lee YT; Leung CB; Lui SF; Lam CW; Lai KN
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):246-8. PubMed ID: 7620696
[TBL] [Abstract][Full Text] [Related]
14. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial.
Holdaas H; Jardine AG; Wheeler DC; Brekke IB; Conlon PJ; Fellstrøm B; Hammad A; Holme I; Isoniemi H; Moore R; Rowe PA; Sweny P; Talbot DA; Wadstrøm J; Østraat Ø
Kidney Int; 2001 Nov; 60(5):1990-7. PubMed ID: 11703619
[TBL] [Abstract][Full Text] [Related]
15. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
[TBL] [Abstract][Full Text] [Related]
16. Fluvastatin in renal transplantation.
Hadjigavriel M; Kyriakides G
Transplant Proc; 1997 Nov; 29(7):3050. PubMed ID: 9365661
[No Abstract] [Full Text] [Related]
17. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
Holdaas H; Fellström B; Jardine AG; Holme I; Nyberg G; Fauchald P; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Olsson AG; Hartmann A; Solbu DO; Pedersen TR;
Lancet; 2003 Jun; 361(9374):2024-31. PubMed ID: 12814712
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients.
Akiyama T; Ishii T; Imanishi M; Nishioka T; Matsuura T; Kurita T
Transplant Proc; 2001 May; 33(3):2115-8. PubMed ID: 11377469
[No Abstract] [Full Text] [Related]
19. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.
Peters TK; Muratti EN; Mehra M
Am J Med; 1994 Jun; 96(6A):79S-83S. PubMed ID: 8017471
[TBL] [Abstract][Full Text] [Related]
20. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient.
Kosch M; Barenbrock M; Suwelack B; Schaefer RM; Rahn KH; Hausberg M
Am J Kidney Dis; 2003 May; 41(5):1088-96. PubMed ID: 12722044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
